Download ASCO Planner 2015

Roche Investor Relations
ASCO Planner 2015
Saturday, May 30
Session Title: Developmental Therapeutics—Immunotherapy
Session Type: Poster Session
Date: Sat, May 30
Location: S Hall A
Time: 8:00 AM - 11:30 AM

Poster Board: #341
Molecular, immune and histopathological characterization of NSCLC based on PDL1
expression on tumor and immune cells and association with response to the anti-PDL1
antibody MPDL3280A. (Abstract #3015)
Scott N. Gettinger, MD
Session Title: Breast Cancer—HER2/ER
Session Type: Poster Session
Date: Sat, May 30
Location: S Hall A
Time: 8:00 AM - 11:30 AM

Poster Board: #74
Total pathologic complete response (tpCR) and event-free survival (EFS) with subcutaneous
(SC) or intravenous (IV) trastuzumab in HER2-positive early breast cancer (EBC). (Abstract
#585)
Christian Jackisch, MD
F. Hoffmann-La Roche Ltd
4070 Basel
Investor Relations
Tel. +41 61 68-88880
Switzerland
email:
Fax +41 61 69-10014
[email protected]
www.roche.com
Session Title: Melanoma/Skin Cancers
Session Type: Oral Abstract Session
Date: Sat, May 30
Location: E354b
Time: 1:15 PM - 4:15 PM
Chair and/or Co-Chairs: Axel Hauschild, MD, and Sekwon Jang, MD

3:15 PM - 3:27 PM
Update of progression-free survival (PFS) and correlative biomarker analysis from coBRIM:
Phase III study of cobimetinib (cobi) plus vemurafenib (vem) in advanced BRAF-mutated
melanoma. (Abstract #9006)
James M. G. Larkin, MD, PhD
Session Title: Health Services Research and Quality of Care
Session Type: Oral Abstract Session
Date: Sat, May 30
Location: S102
Time: 1:15 PM - 4:15 PM
Chair and/or Co-Chairs: Helen M. Parsons, PhD, MPH, and Ann H. Partridge, MD, MPH

2:27 PM - 2:39 PM
Cost of chemotherapy for metastatic colorectal cancer with either bevacizumab or cetuximab:
Economic analysis of CALGB/SWOG 80405. (Abstract #6504)
Deborah Schrag, MD, MPH
Session Title: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Session Type: Oral Abstract Session
Date: Sat, May 30
Location: E Hall D1
Time: 3:00 PM - 6:00 PM
Chair and/or Co-Chairs: Scott N. Gettinger, MD, and Charles M. Rudin, MD, PhD

3:00 PM - 3:12 PM
Bevacizumab 15mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in Malignant
Pleural Mesothelioma (MPM): Results of the IFCT-GFPC-0701 MAPS randomized phase 3 trial.
(Abstract #7500)
Gerard Zalcman, MD, PhD
Sunday, May 31
Session Title: Lung Cancer—Non-Small Cell Metastatic
Session Type: Oral Abstract Session
Date: Sun, May 31
Location: N Hall B1
Time: 8:00 AM - 11:00 AM
Chair and/or Co-Chairs: Luis G. Paz-Ares, MD, PhD, and Nithya Ramnath, MD

10:24 AM - 10:36 AM
Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC)
patients who have failed prior crizotinib: An open-label, single-arm, global phase 2 study
(NP28673). (Abstract #8008)
Sai-Hong Ignatius Ou
Session Title: Lymphoma and Plasma Cell Disorders
Session Type: Poster Session
Date: Sun, May 31
Location: S Hall A
Time: 8:00 AM - 11:30 AM



Poster Board: #352
Interim results from a dose-escalation study of the BCL-2 inhibitor venetoclax (ABT-199/GDC0199) plus bendamustine (B) and rituximab (R) in patients (pts) with relapsed/refractory (R/R)
Non-Hodgkin’s Lymphoma (NHL). (Abstract #8535)
Sven De Vos, MD, PhD
Poster Board: #394
Phase I interim safety and efficacy of venetoclax (ABT-199/GDC-0199) monotherapy for
relapsed/refractory (R/R) multiple myeloma (MM). (Abstract #8576)
Shaji Kumar, MD
Poster Board: #398
Phase 1b interim results: Venetoclax (ABT-199/GDC-0199) in combination with bortezomib
(BTZ) and dexamethasone (Dex) in relapsed/refractory (R/R) multiple myeloma (MM).
(Abstract #8580)
Cyrille Touzeau, MD
Session Title: Plenary Session Including the Science of Oncology Award and Lecture
Session Type: Plenary Session
Date: Sun, May 31
Location: N Hall B1
Time: 1:00 PM - 4:00 PM
Chair and/or Co-Chairs: Peter P. Yu, MD, FACP, FASCO, and Alan P. Venook, MD
Session Title: Immunotherapy in Lung Cancer: A Paradigm Shift
Session Type: Clinical Science Symposium
Date: Sun, May 31
Location: E Hall D1
Time: 4:30 PM - 6:00 PM
Chair and/or Co-Chairs: Nathan A. Pennell, MD, PhD, and Geoffrey R. Oxnard, MD

4:42 PM - 4:54 PM
Efficacy, safety and predictive biomarker results from a randomized phase II study comparing
MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR). (Abstract #8010)
Alexander I. Spira, MD, PhD
Monday, June 1
Session Title: Breast Cancer—HER2/ER
Session Type: Oral Abstract Session
Date: Mon, Jun 1
Location: N Hall B1
Time: 8:00 AM - 11:00 AM
Chair and/or Co-Chairs: Priya Rastogi, MD, and Tufia C. Haddad, MD




8:12 AM - 8:24 AM
Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine
therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB 40503
(Alliance). (Abstract #501)
Maura N. Dickler, MD
9:48 AM - 10:00 AM
Five-year analysis of the phase II NeoSphere trial evaluating four cycles of neoadjuvant
docetaxel (D) and/or trastuzumab (T) and/or pertuzumab (P). (Abstract #505)
Luca Gianni, MD
10:00 AM - 10:12 AM
Efficacy of 12-weeks of neoadjuvant TDM1 with or without endocrine therapy in HER2-positive
hormone-receptor-positive early breast cancer: WSG-ADAPT HER2+/HR+ phase II trial.
(Abstract #506)
Nadia Harbeck, MD, PhD
10:12 AM - 10:24 AM
Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs
trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from
the MARIANNE study. (Abstract #507)
Paul Anthony Ellis
Session Title: Gynecologic Cancer
Session Type: Oral Abstract Session
Date: Mon, Jun 1
Location: E354b
Time: 8:00 AM - 11:00 AM
Chair and/or Co-Chairs: Rebecca S. Kristeleit, MD, PhD, and John K. Chan, MD

9:12 AM - 9:24 AM
Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum-resistant ovarian
cancer (PROC): AGO-OVAR 2.20/ENGOT-ov14/PENELOPE double-blind placebo-controlled
randomized phase III trial. (Abstract #5504)
Christian Kurzeder, MD
Session Title: Lung Cancer—Non-Small Cell Metastatic
Session Type: Poster Session
Date: Mon, Jun 1
Location: S Hall A
Time: 8:00 AM - 11:30 AM




Poster Board: #341
A phase II, open-label, multicenter study of the ALK inhibitor alectinib in an ALK+ non-smallcell lung cancer (NSCLC) U.S./Canadian population who had progressed on crizotinib
(NP28761). (Abstract #8019)
Leena Gandhi, MD, PhD
Poster Board: #350
Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1–
selected patients with non-small cell lung cancer (NSCLC). (Abstract #8028)
David R. Spigel, MD
Poster Board: #351
Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A
(anti-PDL1) in non-small cell lung cancer (NSCLC): update from a phase Ia study. (Abstract
#8029)
Leora Horn, MD, MSc
Poster Board: #352
Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet
chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). (Abstract
#8030)
Stephen V. Liu, MD
Session Title: Lymphoma
Session Type: Oral Abstract Session
Date: Mon, Jun 1
Location: E450
Time: 9:45 AM - 12:45 PM
Chair and/or Co-Chairs: Owen A. O'Connor, MD, PhD, and Grzegorz S. Nowakowski, MD

10:09 AM - 10:21 AM
GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine
compared with bendamustine alone in patients with rituximab-refractory indolent nonHodgkin lymphoma. (Abstract #LBA8502)
Laurie Helen Sehn, MDCM, MPH
Session Title: Genitourinary (Nonprostate) Cancer
Session Type: Oral Abstract Session
Date: Mon, Jun 1
Location: E Arie Crown Theater
Time: 9:45 AM - 12:45 PM
Chair and/or Co-Chairs: Guru Sonpavde, MD, and Ana M. Molina, MD

9:57 AM - 10:09 AM
A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial
bladder cancer (UBC). (Abstract #4501)
Daniel Peter Petrylak, MD
Session Title: Melanoma/Skin Cancers
Session Type: Poster Session
Date: Mon, Jun 1
Location: S Hall A
Time: 1:15 PM - 4:45 PM


Poster Board: #263
Extended follow-up results of phase Ib study (BRIM7) of vemurafenib (VEM) with cobimetinib
(COBI) in BRAF-mutant melanoma. (Abstract #9020)
Anna C. Pavlick, DO
Poster Board: #267
Impact of treatment breaks on vismodegib patient outcomes: Exploratory analysis of the
STEVIE study. (Abstract #9024) Reinhard Dummer, MD